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Available online xxxxWithin EuroFlow, we recently developed screening tubes for hematological malignancies and immune deﬁcien-
cies. Pipetting of antibodies for such 8-color 12-marker tubes however is time-consuming and prone to opera-
tional mistakes. We therefore evaluated dried formats of the lymphocytosis screening tube (LST) and of the
primary immune deﬁciency orientation tube (PIDOT). Both tubes were evaluated on normal and/or on patient
samples, comparing the mean ﬂuorescence intensity of speciﬁc lymphocyte populations. Our data show that
the dried tubes and liquid counterparts give highly comparable staining results, particularly when analyzed in
multidimensional plots. In addition, the use of dried tubes may result in a reduced staining variability between
different samples and thereby contributes to the generation of more robust data. Therefore, by using ready-to-
use reagents in a dried single test tube format, the laboratory efﬁciency and quality will be improved.
© 2017 ErasmusMC, University Medical Center Rotterdam. Published by Elsevier B.V. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
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Flow cytometry1. Introduction
Current clinical immunophenotyping protocols generally include ≥
8-color tubes, allowing precise characterization of normal, reactive
and neoplastic leukocyte populations (van Dongen et al., 2012a;
Theunissen et al., 2016; Berkowska et al., 2014). By combining multiple
antibodies in the same ﬂuorochrome position, the number of antibodies
in single tubesmay even be larger (Quijano et al., 2009). For example, in
the EuroFlow Lymphocytosis Screening Tube (LST), both CD20 and CD4
are labeled with Paciﬁc Blue (PacB), CD56 and Surface membrane (Sm)
Immunoglobulin (Ig)Kappa are both conjugated with PE, CD8 and
SmIgLambda are both conjugated with FITC, and CD19 and T-cell recep-
tor (TCR)γδ are both conjugated with PC7, resulting in an 8-color tube
with 12 markers (van Dongen et al., 2012a). Comparably, in thelogy, Erasmus MC, University
erdam, The Netherlands.
H.J. van der Velden).
ter Rotterdam. Published by Elsevier
.H.J., et al., Optimization and t
://dx.doi.org/10.1016/j.jim.20EuroFlow orientation tube for primary immunodeﬁciencies (PIDOT)
CD8 and SmIgD are both conjugated with FITC, CD16 and CD56 with
PE, CD4 and SmIgM with PerCP-Cy5.5, and TCRγδ and CD19 with PC7,
also resulting in an 8-color tube with 12 markers.
Pipetting of antibodies for such tubes is time-consuming and is
prone to operational mistakes (1–4% of samples in our experience). In
contrast, the use of dried tubesmay result in a reduced staining variabil-
ity between different samples due to prolonged stability of the dried re-
agent mixes, and thereby contributes to the generation of more robust
data. Therefore, the laboratory efﬁciency and quality may be improved
by using ready-to-use reagents in a dried single-test tube format
(Hedley et al., 2015).
Within EuroFlow, the screening tubes and the diagnostic antibody
panelswere licensed to BD Biosciences and Cytognos,who aim to devel-
op dried tubes for the various EuroFlow screening tubes as well as clas-
siﬁcation tubes. In this report, we describe the development and testing
of the EuroFlow LST tube, which was released on the market in 2015 by
BD Biosciences with the name of BD OneFlow™ LST (BD Biosciences,
2016), and the EuroFlow PIDOT tube, to be released by Cytognos SL.B.V. This is an open access article under the CC BY license (http://creativecommons.org/
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2.1. Dried tubes
Dried BD LST tubes were prepared by BD Biosciences (San Jose, CA,
USA) (Chan et al., 2016) whereas the dried format of the PIDOT tube
was manufactured by Cytognos SL (Salamanca, Spain). For the dried
BD OneFlow™ LST tube, the reagents were dried in BD's proprietary
buffer formulation to preserve the activity of the antibodies and extend
the life and stability of the reagents.
2.2. Samples
The BD™ LST prototype tubes were evaluated on peripheral blood
(PB) and bone marrow (BM) samples from normal donors, deﬁned as
individuals without any known clonal hematological disorder and
with no evidence of such disorders in the tested sample (lot #1
(2198715): n = 14 PB; lot #2 (130228): n = 13 PB and 5 BM). The
ﬁnal lot (lot #3; 130716) was ﬁrst evaluated on normal PB (n = 15)
and subsequently tested on PB (n= 7) and BM samples (n= 6) of pa-
tients with mature B-cell malignancies. Lots were tested and data col-
lected in two EuroFlow centers (Erasmus MC, Rotterdam, The
Netherlands, and University of Salamanca, Salamanca, Spain). The ﬁnal
lot was subsequently clinically evaluated in a side-by-side comparison
study between the EuroFlow liquid reagents and the BD OneFlow™
LST tube, performed at three external clinical sites. A total of 123 PB
specimens, 53 BM specimens, and 31 fresh lymph node (LN) specimens
were enrolled in this study.
The EuroFlow PIDOT dried tube was evaluated on PB samples from
25 normal donors, deﬁned as individuals with no past history of immu-
nological or hematological disorders and with no evidence of such dis-
orders in the tested sample. Data were collected in four EuroFlow
centers (Charles University, Prague, Czech Republic; Erasmus MC, Rot-
terdam, The Netherlands; Ghent University, Ghent, Belgium; University
of Salamanca, Salamanca, Spain).
All sampleswere collected according to the guidelines of theMedical
Ethical Committee of the University of Salamanca and Erasmus MC
(MEC-2007-234).
2.3. Staining protocols
All samples were stained in parallel with the EuroFlow liquid LST re-
agent home-made cocktail or the PIDOT combination (“liquid” format)
containing the reference reagents, and the BD dried LST tube or the
Cytognos dried PIDOT tube (see Table 1 (BD OneFlow™ LST) and
Table 2 (PIDOT)). Of note, whereas the EuroFlow liquid LST reagent
cocktail contained the Paciﬁc Blue (PacB) and Paciﬁc Orange (PO)Table 1
LST tube: EuroFlow reference reagents and reagents in the dried BD LST tube.
EuroFlow reference reagent
MoAb Manufacturer Clone Catalogu
1 CD8-FITC Cytognos UCH-T4 CYT-SLP
2 Igλ-FITC Cytognos Polyclonal
3 CD56-PE Cytognos C5.9
4 Igκ-PE Cytognos Polyclonal
5 CD5-PerCPCy5.5 BD L17F12 341109
6 CD19-PC7 Beckman Coulter J3-119 IM3628
7 TCRγδ-PC7 BD 11F2 649806
8 CD3-APC BD SK7 345767
9 CD38-APCH7 BD HB7 646786
10 CD20-PacB BioLegend 2H7 302328
11 CD4-PacB BioLegend RPA-T4 300521
12 CD45-PacO Invitrogen HI30 MHCD45
BD: BD Biosciences.
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zon™ Violet (HV)-450 and the HV-500-C ﬂuorochromes instead. For
the PIDOT tube, the CD27-Brilliant violet (BV)421 and CD45RA-BV510
were not included in the dried tube, and were dropped-in when staining
with the dried tube. All samples were stained with LST according to the
EuroFlow Standard Operating Procedure (SOP) (Kalina et al., 2012). Brieﬂy,
PB or BM sampleswere ﬁrstwashed 2 or 3 times (see Results) usingwash-
ing buffer (phosphate buffered saline (PBS) containing 0.5% bovine serum
albumin (BSA) and 0.09% sodium azide (NaN3)) and subsequently stained
with the antibodies for 15 or 30 min (see Results) at room temperature in
the dark. All stainings were performed in a ﬁnal volume of 100 μl: 50 μl
washed BM or PB and 50 μl of antibodies for the EuroFlow tubes and
50 μl washed BM or PB and 50 μl washing buffer for the dried BD LST
tube. For the PIDOT tubes, samples were stained according to the
EuroFlow bulk lyse SOP (for detailed protocol, see www.EuroFlow.org)
(Theunissen et al., 2016; Flores-Montero et al., 2017). Brieﬂy, 50ml of am-
monium chloride solution was mixed with 2 ml of PB, and incubated for
15 min at room temperature (RT) to lyse non-nucleated red cells. Then,
nucleated cellswerewashedwithwashing buffer and counted in a hema-
tological analyzer. In each case, 2 × 106 nucleated cellswere subsequently
stained in a ﬁnal volume of 100 μl (30 min at RT); afterward, 2 ml of BD
FACS™ Lysing Solution (BD Biosciences) diluted 1/10 (vol/vol) in distilled
water was added and cells incubated for another 10 min (RT), washed
and resuspended in washing buffer (ﬁnal volume of 500 μl).
2.4. Instrument settings and data acquisition
Instrument settings and data acquisition were performed following
the speciﬁc EuroFlow SOP (Kalina et al., 2012) using BD™ Cytometer
Setup and Tracking (CS&T) beads (BD Biosciences) and Rainbow beads
(Spherotech, Lake Forest, IL, USA). Speciﬁc compensation settings for
each ﬂuorochrome conjugate were used, whenever necessary. A mini-
mum of 50.000 total events (LST) or 1.000.000 total events (PIDOT)
were acquired on a BD FACSCanto™ II ﬂow cytometer (BD Biosciences).
Appropriate instrument performance and laboratory procedures were
conﬁrmedby results obtained in the EuroFlowquality assessment rounds
(Kalina et al., 2015). For the LST clinical validation study, the BD
OneFlow™ LST tubewas acquired on a BD FACSCanto™ IIﬂow cytometer
set-up using the BD OneFlow Set-up beads, BD FC Beads for compensa-
tion, and the BD OneFlow™ LST reagents (BD Biosciences, 2016).
2.5. Data analysis
Data were analyzed using Inﬁnicyt software (van Dongen et al.,
2012b). For evaluation of normal PB/BM samples, mature lymphocytes
and theirmajor cell subsetswere used as reference populations; the ref-
erence populations and the corresponding gating strategy are describedTested reagent
e ref. Staining volume (μL/test) BD LST dried format
MoAb Clone
C-50 20 CD8-FITC SK1
Igλ-FITC Monoclonal
CD56-PE MY31
Igκ-PE Monoclonal
15 CD5-PerCPCy5.5 L17F12
5 CD19-PC7 SJ25C1
3 TCRγδ-PC7 11F2
3 CD3-APC SK7
3 CD38-APC HB7
1 CD20-HV450 L27
2 CD4-HV450 SK3
30 5 CD45-HV500-C 2D1
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Table 2
PIDOT tube: EuroFlow reference reagents and reagents in the dried format PIDOT tube.
EuroFlow reference reagent Tested reagent
MoAb Manufacturer Clone Catalogue ref. Staining volume (μL/test) PIDOT dried tube
MoAb Clone
1 CD8-FITC BD SK1 345271 5 CD8-FITC UCHT-4
2 IgD-FITC Biolegend IA6-2 348205 1.25 IgD-FITC IADB6
3 CD16-PE BD 3G8 555407 5 CD16-PE 3G8
4 CD56-PE Cytognos C5.9 CYT-56PE 5 CD56-PE C5.9
5 CD4-PerCPCy5.5 BDB SK3 332772 7 CD4-PerCPCy5.5 RPA-T4
6 IgM-PerCPCy5.5 Biolegend MHM-88 314511 2 IgM-PerCPCy5.5 MHM-88
7 TCRγδ-PC7 BD 11F2 549806 5 TCRγδ-PC7 TCR-1
8 CD19-PC7 Beckman Coulter J3-119 IM3628 1 CD19-PC7 19–1
9 CD3-APC BD SK7 345767 2.5 CD3-APC UCHT-1
10 CD45-APCH7 BD 2D1 641417 2 CD45-APCH7 HI30
11 CD27-BV421a BD M-T271 562513 1
12 CD45RA-BV510b BD HI100 563031 2.5
BD: BD Biosciences.
a In one laboratory CD27 BV421 from BioLegend (O323, catalogue reference 302,824; 1 μl/test) was used; this is an ofﬁcial EuroFlow-approved alternative antibody.
b In one laboratory CD45 BV510 from BioLegend (HI100, catalogue reference 304,142; 2.5 μl/test) was used; this is an ofﬁcial EuroFlow-approved alternative antibody.
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sponding positive and negative reference population, themean ﬂuores-
cence intensity (MFI) and coefﬁcient of variation (CV) was recorded for
both the liquid format and the dried format reagent mixes. The differ-
ence was calculated by the formula (MFI dried tube-MFI liquid
format)/(MFI liquid format) ∗ 100%. Since the expression of markers
on abnormal B-cells varied between different patients, it was not appro-
priate to use the average values of all abnormal populations. Therefore,
for the patient samples only the samples being positive for a speciﬁc
marker (MFI N 1000) were taken into account for the evaluation. For
the LST clinical validation study, samples were identiﬁed as being
“Follow-up needed” or “No Follow-up needed” using the two systems,
and the level of agreement was determined.
2.6. Acceptance criteria
MFI values of the normal reference populations obtained using the
dried tubes were compared with the MFI values of the reference popu-
lations obtained using the liquid tubes. If the percentage difference
(see formula above) was N30% (either up or down), the difference
was considered to be signiﬁcant; if the difference was b30%, the two re-
agents were considered equivalent.
3. Results
3.1. LST tube
3.1.1. Evaluation of BD™ LST prototype #1 on normal samples
As shown in Table 5, when compared to the reference (liquid)
reagent cocktail, the majority of reagents tested in the dried formatTable 3
Positive and negative reference lymphocyte populations used for the various markers and thei
Target marker Positive reference population Gating
CD8 CD8+ T-cells CD8hi/C
IgLambda Igλ+ B-cells CD20+
IgKappa Igκ+ B-cells CD20+
CD56 NK-cells CD3−/C
CD5 CD4+ T-cells CD4+/C
CD19 B-cells CD20hi/
TCRγδ TCRγδ+ T-cells TCRγδ+
CD3 CD4+ T-cells CD4+/C
CD20 B-cells CD19+
CD4 CD4+ T-cells CD4+/C
CD38 NK-cells CD3−/C
NA: not applicable; LST: lymphocytosis screening tube.
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tion: Sm IgLambda-FITC; CD8-FITC; CD56-PE; SmIgKappa-PE; CD5-
PerCPCy5.5; CD3-APC; CD38-APCH7; CD20-HV450; CD4-HV450 and
CD45-HV500C. Nevertheless, some of these reagents (CD8-FITC, CD4-
HV450) showed a tendency to display a lower expression when com-
pared with the reference reagents (Table 5). CD19-PC7 (−31%) and
anti-TCRγδ-PC7 (+32%) showed larger differences, outside the accep-
tance criteria. Background staining was generally somewhat higher in
the dried tube (Table 5), but this had no impact on data analysis and
the results obtained. Furthermore, signiﬁcant differences were found
for SmIgKappa and, to a lesser extent, SmIgLambda staining between
the two EuroFlow testing centers (data not shown), probably related
to slight differences in the washing steps.
3.1.2. Evaluation of BD™ LST prototype #2 on normal samples
Based on the variation observed between the dried and liquid re-
agent cocktails with the ﬁrst prototype, the incubation time was in-
creased to 30 min; this did not result in clearly higher ﬂuorescence
intensities but appeared to be more robust (plateau phase of staining)
than shorter incubation time (data not shown). In addition, three pre-
washes were introduced to reduce the stain variability for Ig light
chains. Furthermore, while prototype #1was the EuroFlow original rec-
ipe just in dry format, in prototype #2 all antibodies were set to a stable
titer. As shown in Table 5, the majority of reagents tested in the dried
format (prototype 2) performed within the acceptance limits of the
evaluation. In contrast, the CD56-PE and SmIgKappa-PE markers
showed higher differences, outside the 30% arbitrary acceptance criteria
established. Finally, a higher background staining was observed using
the dried tube for both FITC and PC7 (Table 5), but this was no longer
detected for the other ﬂuorochromes.r gating strategy for the LST tube.
strategy Negative reference population
D45hi/SSClo CD4+ T-cells
/CD19+/Igκ−/CD3− CD4+ T-cells
/CD19+/Igλ−/CD3− CD4+ T-cells
D19−/CD20−/CD45hi/SSClo/CD56+ CD4+/CD56− T-cells
D45hi/SSClo B-cells
CD45hi/SSClo/CD3− NK-cells
/CD45hi/SSClo/CD3very high NK-cells
D45hi/SSClo B-cells
/CD45hi/SSClo/Igκ+ or Igλ+/CD3− NK-cells
D45hi/SSClo NK-cells
D19−/CD20−/CD45hi/SSClo/CD56+ NA
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Table 4
Positive and negative reference lymphocyte populations for the various markers and their gating strategy for the PIDOT.
Target marker Positive reference population Gating strategy Negative reference population
CD8 CD8+ T-cells CD3+/CD4−/CD8+/CD19−/CD45hi/TCRγδ−/FSClo/SSClo CD4+ T-cells
SmIgD preGC B-cells CD3−/CD19+/CD16 + CD56−/CD27−/CD45hi/smIgM+/smIgD+/FSClo/SSClo Switched memory. B-cells
CD16 + CD56 NK-cells CD3−/CD19−/CD16 + CD56hi/CD45hi/FSClo/SSClo CD4+ T-cells
CD4 CD4+ T-cells CD3+/CD4+/CD8−/CD19−/CD45hi/TCRγδ−/FSClo/SSClo CD8+ T-cells
SmIgM Unswitched memory B-cells CD3−/CD19+/CD16 + CD56−/CD27+/CD45hi/smIgMhi/smIgD+/FSClo/SSClo Switched memory B-cells
TCRγδ TCRγδ+ T-cells CD3+/CD19−/CD45hi/TCRγδ+/FSClo/SSClo NK-cells
CD19 B-cells CD3−/CD19+/CD16 + CD56−/CD45hi/FSClo/SSClo NK-cells
CD3 T-cells CD3+/CD19−/CD45hi/FSClo/SSClo NK-cells
NA: not applicable; GC: germinal center; PIDOT: primary immunodeﬁciency orientation tube.
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Prototype #3 had reduced concentrations of TCRγδ-PC7 and
SmIgLambda-FITC to decrease non-speciﬁc staining. As shown in
Table 5, the majority of reagents tested in the dried format (prototype
3) on 15 normal PB samples performed within the acceptance limits
of the evaluation. CD19-PC7 (−41%) and SmIgLambda-FITC (−62%)
showed larger differences, failing to fulﬁll the acceptance criteria. A rep-
resentative example is shown in Fig. 1. Presenting the data of both the
liquid EuroFlow tube and the dried tube in an automated population
separator (APS) plot showed however highly overlapping populations,
indicating that the variations seen for some individual markers did
not signiﬁcantly impact the identiﬁcation of the corresponding cell
populations via multidimensional analysis (Fig. 2). Since the CD19-
PC7 MFI value could not be further improved (technical limit of conju-
gation) and since B-cells could still easily be identiﬁed, CD19-PC7 was
accepted in its current format. Although the SmIgLambda staining was
less than the original EuroFlow liquid staining, the SmIgKappa and
SmIgLambda positive populations still could well be separated and
therefore the lower SmIgLambda intensity of the dried tube was not
considered to negatively impact the analysis. Therefore, prototype 3Table 5
Results of the comparison between the LST liquid reagents and
blood samplesa.
Negative reference popul
Antibody Lot 1 Lot 2
SmIgLambda–FITC 116% 205%
SmIgKappa–PE 174% –35%
CD8–FITC 116% 205%
CD56–PE 174% –35%
CD5–PerCP–Cy5.5 60% –4%
CD19–PC7 389% 172%
TCRγδ–PC7 389% 172%
CD3–APC 153% –11%
CD38–APCH7 NA NA
CD4–PacB/HV450 –73% –1%
CD20–PacB/HV450 –73% –1%
CD45–PO/HV500 NA NA
a For each sample, the difference was calculated as follows:
∗100%. Data presented reﬂect themean difference of the analyz
NA = not analyzed. Red numbers indicate those percentages t
erence population; orange numbers indicate those percentages
negative reference population of b30%.
Please cite this article as: van der Velden, V.H.J., et al., Optimization and
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samples.
3.1.4. Evaluation of BD™ LST prototype #3 on patient samples
Prototype #3 was subsequently evaluated on PB (n = 7) and BM
samples (n = 6) of patients with mature B- or T-cell malignancies. In
general, the patterns observed for the abnormal T- and B-cell popula-
tions reﬂected the patterns observed in the normal populations
(Table 6 and Fig. 3). Similarly to the liquid format, the dried format
allowed the identiﬁcation of all normal and abnormal B and T-cell pop-
ulations present in each individual sample.
3.1.4.1. Reproducibility of the intensity of staining on normal samples using
the BDOneFlow™ LST tube. The reproducibility of the EuroﬂowLST stain-
ing among different samples was evaluated for the EuroFlow liquid re-
agents LST tube and the dried BD LST tube. The CV values for both
types of tests were comparable for most markers, except for TCRγδ
and SmIgKappa that were both more robust using the dried BD
OneFlow™ LST tube (Table 7).the three dried BD LST prototypes on normal peripheral
ation Positive reference population
Lot 3 Lot 1 Lot 2 Lot 3
24% 6% 6% –62%
36% –5% –69% –12%
24% –25% –4% –12%
36% –17% –51% –19%
–81% –17% 21% 11%
9% –31% –25% –41%
9% 32% 15% –7%
–28% 21% –1% –8%
NA 0% –17% –6%
–104% –23% –22% –29%
–104% –15% 4% –5%
NA 8% –24% –20%
(MFI dried tube-MFI liquid format)/(MFI liquid format)
ed samples (lot#1: n=14; lot #2: n=18; lot #3: n=15).
hat are outside the acceptance criteria for the positive ref-
that are outside the (arbitrary) acceptance criteria for the
testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as
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Fig. 1. Representative example of a PB sample stained with the EuroFlow LST tube liquid reagents (top row) and the same sample stained with the dried LST tube (prototype 3; bottom
row). Only B-cells are shown (blue: SmIgKappa+; purple: SmIgLambda+). The arrows indicate the two markers with staining intensities over 30% different, between the two tubes. For
data analysis the Inﬁnicyt software (Cytognos) was used.
5V.H.J. van der Velden et al. / Journal of Immunological Methods xxx (2017) xxx–xxx3.1.4.2. Clinical validation of the BDOneFlow™ LST tube. The BDOneFlow™
LST tube was ﬁnally clinically validated by comparing the results with
those obtained using the EuroFlow liquid reagents in a total of 207 spec-
imens. Using bothmethods, abnormal mature B-cells were identiﬁed in
81 samples, abnormal T-cells in 35 samples, abnormal NK-cells in 6
samples, and other abnormalities in 9 samples (e.g. plasma cell disor-
ders); resulting in a total of 131 samples that needed follow-up. Seven-
ty-six samples were deﬁned as normal by both methods. Therefore,
agreement between both methods was obtained in 100% of cases. Eval-
uation of the percentages of themajor lymphocyte populations showedFig. 2.Multidimensional evaluation of the EuroFlow LST tube liquid reagents and the dried LST
median and 2SD contours of the various populations are shown. For data analysis the Inﬁnicyt
Please cite this article as: van der Velden, V.H.J., et al., Optimization and t
examples, J. Immunol. Methods (2017), http://dx.doi.org/10.1016/j.jim.20equivalency of the BD OneFlow™ LST to the EuroFlow liquid reagents
system (BD Biosciences, 2016).
3.2. PIDOT tube
3.2.1. Evaluation of the PIDOT dried tube on normal samples
As shown in Table 8, the majority of the reagents in the dried PIDOT
format tested on 25 normal samples performed within the acceptance
limits of the evaluation. A representative example of the staining ob-
tained by the liquid tube and dried tube is shown in Fig. 4. Slightlytube (prototype 3) stained on the same PB sample, using visualization in an APS plot. The
software (Cytognos) was used. PC: principal component.
esting of dried antibody tube: The EuroFlow LST and PIDOT tubes as
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Table 6
Results of the comparison between the liquid LST reagents and the dried BD LST prototype
#3 on peripheral blood or bone marrow samples from patients with a mature lymphoid
neoplasm.
Reagent na Average difference on positive casesb
IgLambda-FITC 4 −48%
CD8-FITC 2 −12%
IgKappa-PE 7 +8%
CD56-PE – –
CD5-PerCPCy5.5 8 +11%
CD19-PC7 13 −45%
TCRγδ-PC7 – –
CD3-APC 2 +2%
CD38-APCH7 2 +9%
CD4-PacB/HV450 – –
CD20-PacB/HV450 13 −8%
CD45-PO/HV500c 13 −10%
a Please note that not all markers could be assessed in every case, the number of cases
evaluated for eachmarker depending on the cell populations identiﬁed in sufﬁcient num-
bers in the sample.
b Average of the difference between dried and liquid LST format calculated for each in-
dividual marker.
Table 7
Reproducibility of staining intensity on normal samples using the LST liquid tube anddried
BD LST tube.
Marker Population Coefﬁcient of variation of
MFI values
Liquid LST
reagents
Dried LST
tube
CD8-FITC CD8+/CD4- T cells 17% 17%
CD56-PE NK cells 30% 32%
SmIgLambda-FITC Mature IgLambda B cells 27% 26%
SmIgKappa-PE Mature IgKappa B cells 81% 24%
CD5-PerCP Cy5.5 CD4+ T cells 13% 14%
CD19-PE Cy7 Mature B cells 22% 22%
TCRγδ-PE Cy7 CD4-/CD8- or dim/TCRγδ+ 49% 37%
CD3-APC CD4+ T cells 12% 11%
CD38-APC H7 NK cells 73% 72%
CD20-HV450 Mature B cells 16% 18%
CD4-HV450 CD8-/CD4+ T cells 10% 11%
CD45-HV500 CD4+ T cells 7% 7%
Results expressed as coefﬁcient of variation (CV) of themean ﬂuorescence intensity (MFI)
of the speciﬁed marker for 15 peripheral blood samples stained with the liquid and the
dried LST reagents.
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TCRγδ-PC7 (40%), thus failing to fulﬁll the acceptance criteria. However,
presenting the data of both the EuroFlow reagents PIDOT tube and the
dried PIDOT tube visualized in an APS plot showed highly overlapping
populations, indicating that the variations seen for some individual
markers did not signiﬁcantly impact the identiﬁcation of the distinctly
stained cell populations in a multidimensional analysis (Fig. 5). More-
over, when analyzing the reproducibility of the staining among the dif-
ferent samples (Table 9), it was observed that the CD4 MFI was moreFig. 3.Representative example of a PB sample stained in parallel with the EuroFlow liquid reage
green), an abnormal B-cell population (shown in red) was observed. This monoclonal B-cell ly
easily be identiﬁed in both the EuroFlow liquid and dried LST tubes. For data analysis the Inﬁn
Please cite this article as: van der Velden, V.H.J., et al., Optimization and
examples, J. Immunol. Methods (2017), http://dx.doi.org/10.1016/j.jim.20similar between samples using the dried PIDOT tube. Because of this,
CD4-PerCP-Cy5.5 was accepted in its current format.
3.2.2. Reproducibility of the intensity of staining on normal samples using
the dried PIDOT tube
A higher reproducibility of the EuroFlow PIDOT staining among dif-
ferent samples was observed using the dried PIDOT tube. All tested re-
agents showed a lower CV when using the dried PIDOT tube as
compared to the EuroFlow PIDOT tube reagents, evaluated in parallelnts (A) and the dried LST tube (prototype 3; B). In addition to the normal B-cells (shown in
mphocytosis population comprised 0.4% of the leukocytes (19% of the B-cells) and could
icyt software (Cytognos) was used.
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Table 8
Results of the comparison between the Euroﬂow PIDOT liquid reagents and the dried tube
on normal blood samplesa.
Marker Negative reference population Positive reference population
CD8 –36% 10%
SmIgD –17% –4%
CD16+CD56 2% 3%
CD4 18% 35%
SmIgM 6% 6%
TCRγδ 17% 40%
CD19 17% 4%
CD3 95% 21%
CD45 NA 0%
a For each sample, the difference was calculated as follows: (MFI dried tube-MFI liquid
format)/(MFI liquid format) ∗ 100%. Data presented reﬂect the mean difference of the an-
alyzed samples (lot #1: n = 14; lot #2: n = 18; lot #3: n = 15). NA: not analyzed. Red
numbers indicate those percentages that are outside the acceptance (arbitrary) criteria
of b30% for the positive reference population; orange numbers indicate those percentages
that are outside the (arbitrary) acceptance criteria of b30% for the negative reference
population.
7V.H.J. van der Velden et al. / Journal of Immunological Methods xxx (2017) xxx–xxxin the same set of PB samples from 25 healthy controls (Table 9). The
highest difference in the CV between the dried and the liquid format
was observed for CD4-PerCP-Cy5.5 (10% vs. 48%; Table 9), meanwhile
SmIgM and SmIgD showed very small differences in the reproducibility
of the staining (CV of 21% versus 23% and 19% versus 20%, respectively).
In this regard it should be noted that the CV obtained for distinct
reagents tested in their corresponding target population, among
different samples, was most commonly 10%–20% for the dried PIDOT
tube and 20%–40% for the liquid format, except for the expression ofFig. 4. Representative example of a PB sample stained with the EuroFlow liquid reagent (top ro
shown. For data analysis the Inﬁnicyt (Cytognos) software was used.
Please cite this article as: van der Velden, V.H.J., et al., Optimization and t
examples, J. Immunol. Methods (2017), http://dx.doi.org/10.1016/j.jim.20CD16 + CD56 in NK-cells that showed a CV N 100% with both formats
of the EuroFlow PIDOT tube (Table 9).
4. Discussion
Here we report the performance of the dried format of two antibody
cocktail combinations: the EuroFlow LST tube and EuroFlow PIDOT
tube. Both tubes are screening tubes, the LST for patientswith a lympho-
cytosis and the PIDOT for patients suspected of a lymphoid immune de-
ﬁciency. Since both tubes contain 12 different antibodies, pipetting of all
antibodies is time-consuming and is prone to operational mistakes. Op-
erational mistakes, such as accidental omission of one reagent is an
error that can be difﬁcult to uncover in order to repeat the staining pro-
cedure and repetition increases the cost. Therefore, the laboratory efﬁ-
ciency and quality may be improved by the use of ready-to-use
reagents in a dried single-test tube format (Hedley et al., 2015). Our
data show that the developed dried tubes (BD™ OneFlow LST and
PIDOT from Cytognos) give comparable data as the liquid counterparts.
Of note, somemakers showed a difference inMFI comparedwith the re-
spective liquid formats of over 30%, which was arbitrarily deﬁned be-
forehand as the acceptance range. However, these differences were
accepted for several reasons. First, although the SmIgLambda staining
was less bright than the original EuroFlow liquid staining, the
SmIgKappa and SmIgLambda positive populations still could well be
separated and therefore the lower SmIgLambda intensity of the dried
tube was not considered to negatively impact the analysis. Second, for
most markers the difference was minimal and just over 30%
(CD4: 35%, TCRgd: 40%; CD19: ~45%). Finally, once evaluated in aw) vs dried PIDOT tube (lower row). T-cells (red), B-cells (green) and NK-cells (blue) are
esting of dried antibody tube: The EuroFlow LST and PIDOT tubes as
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Fig. 5.Comparison of stainings for distinct target populationswith the EuroFlowPIDOT liquid reagents tube versus thedried tube in a 12-dimensional space. The quality of the separation of
the subsets and clustering of events is represented by the distance among the circles. Each circle represents a single population stainedwith the EuroFlowPIDOT tube liquid reagents or the
dried PIDOT tube and reﬂects themedianﬂuorescence expression for all parameters. Lines represent thehomogeneity of the subpopulations in the 12-dimensional space, expressed as 2SD
of the events from each target population represented. For data analysis the Inﬁnicyt software (Cytognos) was used. PC: principal component.
8 V.H.J. van der Velden et al. / Journal of Immunological Methods xxx (2017) xxx–xxxmultidimensional approach (APS plots), these differences appeared not
to affect the separation of the various populations. Therefore, while the
liquid cocktails and the dried reagent formats do not provide exactly
identical data, both give comparable results when looked in multidi-
mensional analysis. It is therefore anticipated that results obtained
with both tube formats (liquid and dried) can be used in automated gat-
ing and classiﬁcation software tools that are currently being developed
by EuroFlow. (Pedreira et al., 2013).
The use of dried tubes is not only time-saving and less prone to op-
erational mistakes, it also signiﬁcantly reduces the time spent in anti-
body inventory management (ordering of reagents and acceptance
testing of antibodies (one single tube versus 12 individual antibodies),
including all the corresponding registrations). At Erasmus MC, the BD
OneFlow™ LST tube has been used for diagnostic care since its introduc-
tion in 2015, with almost 2000 evaluations being performed yearly.
Similarly, both the BD OneFlow™ LST tube and the PIDOT dried tube
have been introduced in routine diagnostic screening at USAL, with op-
timal performance.
Finally, the use of dried tubes may result in a reduced staining vari-
ability between different samples and thereby contribute to more ro-
bust data. Although biological factors might contribute to differences
in the markers' intensity of expression among healthy controls, some
molecules have shown to be relatively stable among healthy controls.
Accordingly, previous studies have shown that the CV of CD3, CD4,
CD5, CD8, CD19, CD20, and CD45 expression on normal lymphocytesTable 9
Reproducibility of the staining using the Euroﬂow PIDOT liquid reagents and the dried
tube on normal blood samples.
Marker Population Coefﬁcient of variation of MFI
values
Liquid PIDOT
reagents
PIDOT dried
tube
CD8 CD8+ T-cells 26% 18%
smIgD preGC B-cells 20% 19%
CD16 + CD56 NK cells 122% 103%
CD4 CD4+ T-cells 48% 10%
smIgM Unswitched memory B-cells 23% 21%
TCRγδ TCRγδ+ T-cells 22% 16%
CD19 B-cells 21% 18%
CD3 T-cells 30% 19%
CD45 Lymphocytes 40% 14%
Results expressed as coefﬁcient of variation (CV) of themean ﬂuorescence intensity (MFI)
of the speciﬁed marker for 25 peripheral blood samples stained in parallel with the liquid
and the dried PIDOT reagents. GC: germinal center.
Please cite this article as: van der Velden, V.H.J., et al., Optimization and
examples, J. Immunol. Methods (2017), http://dx.doi.org/10.1016/j.jim.20are between 7% and 33%, within a single laboratory and using the
same instrument (Bikoue et al., 1996). In line with this, the EuroFlow
quality assessment programhas shown that CVs below 30% are reached
for CD19, CD45, CD4, CD8 and CD3 evaluated in different healthy con-
trols from different laboratories, when instrument setup is strictly stan-
dardized (e.g. photomultiplier tube (PMT) voltages and ﬂuorescence
compensation values) and the EuroFlow staining protocols are applied)
(Kalina et al., 2015). However, it is not clearwhether variability ismost-
ly dependent on normal biological factors among individuals or if there
are other technical variations that might be affecting the reproducibility
(e.g. pipetting differences). The results present in this study suggest that
CV values b20% can be reached for most markers evaluated in healthy
controls when using dried tubes, even among samples from different
centers. Next to the stable markers reported above, we observed that
SmIg staining (SmIgM, SmIgD, SmIgKappa, SmIgLambda) also showed
a CV b30% among different healthy donors, despite the extensive sur-
face Ig staining protocol with more than three washing steps. In con-
trast, a higher biological variation was observed for CD16 + CD56
staining of NK-cells, TCRγδ staining on T-cells, and CD38 expression
on B-cells. This is likely related to differential expression of these
markers by different cell subsets or their dependence on the activation
status, and the afﬁnity of the antibody clone used (Lima et al., 2001;
Perez-Andres et al., 2010).
In conclusion, dried reagent tubes with staining characteristics com-
parable to the liquid counterpart have been developed and may im-
prove both laboratory efﬁciency and the quality of immunophenotypic
data. Dried tubesmay also contribute to increased staining reproducibil-
ity (generally resulting in CV values below 20%), whichwill increase the
capacity of ﬂow cytometry to better detect small changes in the expres-
sion levels of individual markers and immunophenotypic proﬁles.
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